Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
Recurrent Head and Neck Cancer|Head and Neck Cancer|Head and Neck Neoplasms|Metastatic Cancer
DRUG: Durvalumab|DRUG: Cetuximab
Objective response rate, Imaging review using RECIST 1.1, 24 months
Adverse events, Percentage of adverse events using CTCAE v 5.0, 24 months|Disease control rate, Combined complete response, partial response, and stable disease, 6 months|Progression-free survival, Imaging review using RECIST 1.1, 24 months|Overall survival, Date of on treatment to date of death, 24 months|Duration of response, Date of initial response to progressive disease, 24 months
This research study is designed to see if the study drug, durvalumab, will work better with cetuximab than either medicine alone along with the evaluation of side effects of the drug combination.